example
-
BRITE list
-
pathway list
-
inferred list -
details & download
inferred list
-
new - new
(0)
-
training - new
(42)
-
new - training
(0)
-
training - training
(0)
-
all
(495)
| Drug | Target | Prediction<br> score | Interaction type<br> [drug - target] |
|---|---|---|---|
| D00293, Diazepam | hsa:2555, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha2 | 1 | known |
| D00293, Diazepam | hsa:2558, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha5 | 1 | known |
| D00293, Diazepam | hsa:2566, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma2 | 1 | known |
| D00293, Diazepam | hsa:2554, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha1 | 0.9986 | known |
| D00293, Diazepam | hsa:2565, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma1 | 0.9968 | known |
| D00293, Diazepam | hsa:2559, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha6 | 0.9968 | known |
| D00293, Diazepam | hsa:2556, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha3 | 0.9961 | known |
| D00293, Diazepam | hsa:2560, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta1 | 0.9913 | known |
| D00293, Diazepam | hsa:2561, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta2 | 0.9908 | known |
| D00293, Diazepam | hsa:2562, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta3 | 0.9837 | known |
| D00293, Diazepam | hsa:2567, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma3 | 0.9814 | known |
| D00293, Diazepam | hsa:2557, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha4 | 0.9805 | known |
| D00365, Lorazepam | hsa:2558, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha5 | 0.9742 | known |
| D00365, Lorazepam | hsa:2555, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha2 | 0.9733 | known |
| D00370, Temazepam | hsa:2566, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma2 | 0.9726 | known |
| D00365, Lorazepam | hsa:2566, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma2 | 0.9724 | known |
| D00365, Lorazepam | hsa:2554, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha1 | 0.972 | known |
| D00370, Temazepam | hsa:2558, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha5 | 0.9705 | known |
| D00365, Lorazepam | hsa:2559, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha6 | 0.9701 | known |
| D00370, Temazepam | hsa:2555, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha2 | 0.9696 | known |
| D00365, Lorazepam | hsa:2556, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha3 | 0.9695 | known |
| D00387, Triazolam | hsa:2566, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma2 | 0.9694 | known |
| D00370, Temazepam | hsa:2554, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha1 | 0.9683 | known |
| D00370, Temazepam | hsa:2565, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma1 | 0.9681 | known |
| D00365, Lorazepam | hsa:2565, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma1 | 0.9678 | known |
| D00387, Triazolam | hsa:2558, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha5 | 0.9675 | known |
| D00293, Diazepam | hsa:2563, (RefSeq) gamma-aminobutyric acid type A receptor subunit delta | 0.9674 | known |
| D00293, Diazepam | hsa:2564, (RefSeq) gamma-aminobutyric acid type A receptor subunit epsilon | 0.9672 | known |
| D00370, Temazepam | hsa:2559, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha6 | 0.9666 | known |
| D00387, Triazolam | hsa:2555, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha2 | 0.9665 | known |
| D00370, Temazepam | hsa:2556, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha3 | 0.9659 | known |
| D00225, Alprazolam | hsa:2566, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma2 | 0.9655 | known |
| D00387, Triazolam | hsa:2554, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha1 | 0.9653 | known |
| D00387, Triazolam | hsa:2565, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma1 | 0.9649 | known |
| D00387, Triazolam | hsa:2559, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha6 | 0.9636 | known |
| D00387, Triazolam | hsa:2556, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha3 | 0.9628 | known |
| D00370, Temazepam | hsa:2560, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta1 | 0.9628 | known |
| D00365, Lorazepam | hsa:2560, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta1 | 0.9624 | known |
| D00370, Temazepam | hsa:2561, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta2 | 0.9622 | known |
| D00365, Lorazepam | hsa:2561, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta2 | 0.9618 | known |
| D00225, Alprazolam | hsa:2558, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha5 | 0.9618 | known |
| D00225, Alprazolam | hsa:2555, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha2 | 0.9609 | known |
| D00225, Alprazolam | hsa:2565, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma1 | 0.9609 | known |
| D00387, Triazolam | hsa:2560, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta1 | 0.9596 | known |
| D00293, Diazepam | hsa:2568, (RefSeq) gamma-aminobutyric acid type A receptor subunit pi | 0.9596 | known |
| D00225, Alprazolam | hsa:2554, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha1 | 0.9595 | known |
| D00387, Triazolam | hsa:2561, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta2 | 0.9591 | known |
| D00225, Alprazolam | hsa:2559, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha6 | 0.9579 | known |
| D00225, Alprazolam | hsa:2556, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha3 | 0.9572 | known |
| D00225, Alprazolam | hsa:2560, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta1 | 0.9557 | known |
| D00370, Temazepam | hsa:2562, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta3 | 0.9554 | known |
| D00225, Alprazolam | hsa:2561, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta2 | 0.9552 | known |
| D00365, Lorazepam | hsa:2562, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta3 | 0.9549 | known |
| D00365, Lorazepam | hsa:2557, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha4 | 0.9543 | known |
| D00370, Temazepam | hsa:2567, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma3 | 0.9531 | known |
| D00365, Lorazepam | hsa:2567, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma3 | 0.9526 | known |
| D00387, Triazolam | hsa:2562, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta3 | 0.9522 | known |
| D00370, Temazepam | hsa:2557, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha4 | 0.9508 | known |
| D00329, Flurazepam | hsa:2566, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma2 | 0.95 | known |
| D00387, Triazolam | hsa:2567, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma3 | 0.9499 | known |
| D00329, Flurazepam | hsa:2558, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha5 | 0.9493 | known |
| D00225, Alprazolam | hsa:2562, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta3 | 0.9485 | known |
| D00329, Flurazepam | hsa:2555, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha2 | 0.9485 | known |
| D00387, Triazolam | hsa:2557, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha4 | 0.9478 | known |
| D00457, Quazepam | hsa:2566, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma2 | 0.9474 | known |
| D00329, Flurazepam | hsa:2554, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha1 | 0.9472 | known |
| D00311, Estazolam | hsa:2558, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha5 | 0.9463 | known |
| D00225, Alprazolam | hsa:2567, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma3 | 0.9462 | known |
| D00311, Estazolam | hsa:2555, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha2 | 0.9455 | known |
| D00329, Flurazepam | hsa:2559, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha6 | 0.9455 | known |
| D00329, Flurazepam | hsa:2565, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma1 | 0.9454 | known |
| D00329, Flurazepam | hsa:2556, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha3 | 0.9448 | known |
| D00311, Estazolam | hsa:2554, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha1 | 0.9442 | known |
| D00457, Quazepam | hsa:2558, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha5 | 0.9439 | known |
| D00311, Estazolam | hsa:2566, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma2 | 0.9438 | known |
| D00457, Quazepam | hsa:2555, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha2 | 0.9429 | known |
| D00457, Quazepam | hsa:2565, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma1 | 0.9429 | known |
| D00311, Estazolam | hsa:2559, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha6 | 0.9424 | known |
| D00225, Alprazolam | hsa:2557, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha4 | 0.9421 | known |
| D00311, Estazolam | hsa:2556, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha3 | 0.9418 | known |
| D00457, Quazepam | hsa:2554, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha1 | 0.9416 | known |
| D00280, Clonazepam | hsa:2566, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma2 | 0.9406 | known |
| D00329, Flurazepam | hsa:2560, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta1 | 0.9402 | known |
| D00457, Quazepam | hsa:2559, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha6 | 0.9401 | known |
| D00329, Flurazepam | hsa:2561, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta2 | 0.9397 | known |
| D00370, Temazepam | hsa:2563, (RefSeq) gamma-aminobutyric acid type A receptor subunit delta | 0.9396 | known |
| D00457, Quazepam | hsa:2556, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha3 | 0.9393 | known |
| D00311, Estazolam | hsa:2565, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma1 | 0.9393 | known |
| D00370, Temazepam | hsa:2564, (RefSeq) gamma-aminobutyric acid type A receptor subunit epsilon | 0.9393 | known |
| D00365, Lorazepam | hsa:2563, (RefSeq) gamma-aminobutyric acid type A receptor subunit delta | 0.9392 | known |
| D00365, Lorazepam | hsa:2564, (RefSeq) gamma-aminobutyric acid type A receptor subunit epsilon | 0.9389 | known |
| D00457, Quazepam | hsa:2560, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta1 | 0.9378 | known |
| D00457, Quazepam | hsa:2561, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta2 | 0.9373 | known |
| D00280, Clonazepam | hsa:2558, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha5 | 0.9366 | known |
| D00387, Triazolam | hsa:2563, (RefSeq) gamma-aminobutyric acid type A receptor subunit delta | 0.9365 | known |
| D00387, Triazolam | hsa:2564, (RefSeq) gamma-aminobutyric acid type A receptor subunit epsilon | 0.9362 | known |
| D00280, Clonazepam | hsa:2565, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma1 | 0.9361 | known |
| D00280, Clonazepam | hsa:2555, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha2 | 0.9357 | known |
| D00280, Clonazepam | hsa:2554, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha1 | 0.9344 | known |
| D00311, Estazolam | hsa:2560, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta1 | 0.934 | known |
| D00311, Estazolam | hsa:2561, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta2 | 0.9335 | known |
| D00470, Prazepam | hsa:2566, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma2 | 0.9331 | known |
| D00329, Flurazepam | hsa:2562, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta3 | 0.933 | known |
| D00280, Clonazepam | hsa:2559, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha6 | 0.9328 | known |
| D00225, Alprazolam | hsa:2563, (RefSeq) gamma-aminobutyric acid type A receptor subunit delta | 0.9325 | known |
| D00225, Alprazolam | hsa:2564, (RefSeq) gamma-aminobutyric acid type A receptor subunit epsilon | 0.9324 | known |
| D00280, Clonazepam | hsa:2556, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha3 | 0.932 | known |
| D00370, Temazepam | hsa:2568, (RefSeq) gamma-aminobutyric acid type A receptor subunit pi | 0.9319 | known |
| D00470, Prazepam | hsa:2558, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha5 | 0.9318 | known |
| D00365, Lorazepam | hsa:2568, (RefSeq) gamma-aminobutyric acid type A receptor subunit pi | 0.9316 | known |
| D00430, Secobarbital | hsa:2566, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma2 | 0.9312 | known |
| D00280, Clonazepam | hsa:2560, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta1 | 0.931 | known |
| D00470, Prazepam | hsa:2555, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha2 | 0.931 | known |
| D00329, Flurazepam | hsa:2567, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma3 | 0.9308 | known |
| D00457, Quazepam | hsa:2562, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta3 | 0.9307 | known |
| D00280, Clonazepam | hsa:2561, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta2 | 0.9305 | known |
| D00329, Flurazepam | hsa:2557, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha4 | 0.93 | known |
| D00470, Prazepam | hsa:2554, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha1 | 0.9297 | known |
| D00430, Secobarbital | hsa:2558, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha5 | 0.9289 | known |
| D00387, Triazolam | hsa:2568, (RefSeq) gamma-aminobutyric acid type A receptor subunit pi | 0.9288 | known |
| D00470, Prazepam | hsa:2565, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma1 | 0.9287 | known |
| D00457, Quazepam | hsa:2567, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma3 | 0.9284 | known |
| D00470, Prazepam | hsa:2559, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha6 | 0.9281 | known |
| D00430, Secobarbital | hsa:2555, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha2 | 0.9281 | known |
| D00470, Prazepam | hsa:2556, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha3 | 0.9274 | known |
| D00311, Estazolam | hsa:2557, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha4 | 0.927 | known |
| D00430, Secobarbital | hsa:2554, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha1 | 0.9268 | known |
| D00311, Estazolam | hsa:2562, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta3 | 0.9267 | known |
| D00430, Secobarbital | hsa:2565, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma1 | 0.9267 | known |
| D00430, Secobarbital | hsa:2559, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha6 | 0.9252 | known |
| D00225, Alprazolam | hsa:2568, (RefSeq) gamma-aminobutyric acid type A receptor subunit pi | 0.925 | known |
| D00454, Olanzapine | hsa:3356, (RefSeq) 5-hydroxytryptamine receptor 2A | 0.9248 | known |
| D00457, Quazepam | hsa:2557, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha4 | 0.9247 | known |
| D00311, Estazolam | hsa:2567, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma3 | 0.9246 | known |
| D00430, Secobarbital | hsa:2556, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha3 | 0.9245 | known |
| D00280, Clonazepam | hsa:2562, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta3 | 0.924 | known |
| D00470, Prazepam | hsa:2560, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta1 | 0.9236 | known |
| D00470, Prazepam | hsa:2561, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta2 | 0.9231 | known |
| D00280, Clonazepam | hsa:2567, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma3 | 0.9218 | known |
| D00430, Secobarbital | hsa:2560, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta1 | 0.9217 | known |
| D00430, Secobarbital | hsa:2561, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta2 | 0.9212 | known |
| D00067, Estrone | hsa:2099, (RefSeq) estrogen receptor 1 | 0.9188 | known |
| D00067, Estrone | hsa:2100, (RefSeq) estrogen receptor 2 | 0.9181 | known |
| D00329, Flurazepam | hsa:2563, (RefSeq) gamma-aminobutyric acid type A receptor subunit delta | 0.9175 | known |
| D00280, Clonazepam | hsa:2557, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha4 | 0.9175 | known |
| D00329, Flurazepam | hsa:2564, (RefSeq) gamma-aminobutyric acid type A receptor subunit epsilon | 0.9173 | known |
| D00470, Prazepam | hsa:2562, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta3 | 0.9165 | known |
| D00457, Quazepam | hsa:2563, (RefSeq) gamma-aminobutyric acid type A receptor subunit delta | 0.9152 | known |
| D00499, Pentobarbital | hsa:2566, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma2 | 0.915 | known |
| D00457, Quazepam | hsa:2564, (RefSeq) gamma-aminobutyric acid type A receptor subunit epsilon | 0.9149 | known |
| D00430, Secobarbital | hsa:2562, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta3 | 0.9146 | known |
| D00470, Prazepam | hsa:2567, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma3 | 0.9143 | known |
| D00470, Prazepam | hsa:2557, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha4 | 0.9129 | known |
| D00430, Secobarbital | hsa:2567, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma3 | 0.9124 | known |
| D00499, Pentobarbital | hsa:2558, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha5 | 0.9121 | known |
| D00311, Estazolam | hsa:2563, (RefSeq) gamma-aminobutyric acid type A receptor subunit delta | 0.9115 | known |
| D00311, Estazolam | hsa:2564, (RefSeq) gamma-aminobutyric acid type A receptor subunit epsilon | 0.9113 | known |
| D00499, Pentobarbital | hsa:2555, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha2 | 0.9112 | known |
| D00499, Pentobarbital | hsa:2565, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma1 | 0.9107 | known |
| D00329, Flurazepam | hsa:2568, (RefSeq) gamma-aminobutyric acid type A receptor subunit pi | 0.9101 | known |
| D00499, Pentobarbital | hsa:2554, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha1 | 0.91 | known |
| D00430, Secobarbital | hsa:2557, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha4 | 0.91 | known |
| D00280, Clonazepam | hsa:2563, (RefSeq) gamma-aminobutyric acid type A receptor subunit delta | 0.9085 | known |
| D00499, Pentobarbital | hsa:2559, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha6 | 0.9085 | known |
| D00280, Clonazepam | hsa:2564, (RefSeq) gamma-aminobutyric acid type A receptor subunit epsilon | 0.9083 | known |
| D00499, Pentobarbital | hsa:2556, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha3 | 0.9077 | known |
| D00457, Quazepam | hsa:2568, (RefSeq) gamma-aminobutyric acid type A receptor subunit pi | 0.9077 | known |
| D00499, Pentobarbital | hsa:2560, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta1 | 0.9057 | known |
| D00499, Pentobarbital | hsa:2561, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta2 | 0.9052 | known |
| D00311, Estazolam | hsa:2568, (RefSeq) gamma-aminobutyric acid type A receptor subunit pi | 0.9041 | known |
| D00470, Prazepam | hsa:2563, (RefSeq) gamma-aminobutyric acid type A receptor subunit delta | 0.9014 | known |
| D00280, Clonazepam | hsa:2568, (RefSeq) gamma-aminobutyric acid type A receptor subunit pi | 0.9011 | known |
| D00470, Prazepam | hsa:2564, (RefSeq) gamma-aminobutyric acid type A receptor subunit epsilon | 0.9011 | known |
| D00430, Secobarbital | hsa:2563, (RefSeq) gamma-aminobutyric acid type A receptor subunit delta | 0.8994 | known |
| D00430, Secobarbital | hsa:2564, (RefSeq) gamma-aminobutyric acid type A receptor subunit epsilon | 0.8992 | known |
| D00499, Pentobarbital | hsa:2562, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta3 | 0.8988 | known |
| D00499, Pentobarbital | hsa:2567, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma3 | 0.8967 | known |
| D00470, Prazepam | hsa:2568, (RefSeq) gamma-aminobutyric acid type A receptor subunit pi | 0.894 | known |
| D00499, Pentobarbital | hsa:2557, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha4 | 0.8936 | known |
| D00267, Chlordiazepoxide | hsa:2566, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma2 | 0.8925 | known |
| D00430, Secobarbital | hsa:2568, (RefSeq) gamma-aminobutyric acid type A receptor subunit pi | 0.8921 | known |
| D00267, Chlordiazepoxide | hsa:2558, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha5 | 0.89 | known |
| D00267, Chlordiazepoxide | hsa:2555, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha2 | 0.8892 | known |
| D00283, Clozapine | hsa:3358, (RefSeq) 5-hydroxytryptamine receptor 2C | 0.8889 | known |
| D00267, Chlordiazepoxide | hsa:2565, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma1 | 0.8882 | known |
| D00267, Chlordiazepoxide | hsa:2554, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha1 | 0.8879 | known |
| D00267, Chlordiazepoxide | hsa:2559, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha6 | 0.8864 | known |
| D00267, Chlordiazepoxide | hsa:2556, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha3 | 0.8857 | known |
| D00499, Pentobarbital | hsa:2563, (RefSeq) gamma-aminobutyric acid type A receptor subunit delta | 0.8838 | known |
| D00499, Pentobarbital | hsa:2564, (RefSeq) gamma-aminobutyric acid type A receptor subunit epsilon | 0.8836 | known |
| D00267, Chlordiazepoxide | hsa:2560, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta1 | 0.8834 | known |
| D00267, Chlordiazepoxide | hsa:2561, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta2 | 0.8829 | known |
| D00458, Quetiapine fumarate | hsa:1813, (RefSeq) dopamine receptor D2 | 0.8777 | known |
| D00267, Chlordiazepoxide | hsa:2562, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta3 | 0.8767 | known |
| D00499, Pentobarbital | hsa:2568, (RefSeq) gamma-aminobutyric acid type A receptor subunit pi | 0.8767 | known |
| D00270, Chlorpromazine | hsa:1813, (RefSeq) dopamine receptor D2 | 0.8749 | known |
| D00267, Chlordiazepoxide | hsa:2567, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma3 | 0.8746 | known |
| D00267, Chlordiazepoxide | hsa:2557, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha4 | 0.8718 | known |
| D00304, Divalproex sodium | hsa:253175, (RefSeq) chromodomain Y-linked 1B | 0.868 | known |
| D00432, Nadolol | hsa:153, (RefSeq) adrenoceptor beta 1 | 0.8678 | known |
| D00426, Risperidone | hsa:1813, (RefSeq) dopamine receptor D2 | 0.8677 | known |
| D00304, Divalproex sodium | hsa:203611, (RefSeq) chromodomain Y-linked 2B | 0.8676 | known |
| D00376, Meprobamate | hsa:2558, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha5 | 0.8664 | known |
| D00376, Meprobamate | hsa:2555, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha2 | 0.8656 | known |
| D00458, Quetiapine fumarate | hsa:147, (RefSeq) adrenoceptor alpha 1B | 0.8654 | known |
| D00376, Meprobamate | hsa:2566, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma2 | 0.8654 | known |
| D00185, Estriol | hsa:2099, (RefSeq) estrogen receptor 1 | 0.8647 | known |
| D00454, Olanzapine | hsa:1813, (RefSeq) dopamine receptor D2 | 0.8646 | known |
| D00376, Meprobamate | hsa:2554, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha1 | 0.8645 | known |
| D00185, Estriol | hsa:2100, (RefSeq) estrogen receptor 2 | 0.8641 | known |
| D00138, Scopolamine | hsa:1131, (RefSeq) cholinergic receptor muscarinic 3 | 0.863 | known |
| D00376, Meprobamate | hsa:2559, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha6 | 0.8629 | known |
| D00376, Meprobamate | hsa:2556, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha3 | 0.8623 | known |
| D00454, Olanzapine | hsa:1815, (RefSeq) dopamine receptor D4 | 0.8621 | known |
| D00267, Chlordiazepoxide | hsa:2563, (RefSeq) gamma-aminobutyric acid type A receptor subunit delta | 0.862 | known |
| D00267, Chlordiazepoxide | hsa:2564, (RefSeq) gamma-aminobutyric acid type A receptor subunit epsilon | 0.8618 | known |
| D00138, Scopolamine | hsa:1132, (RefSeq) cholinergic receptor muscarinic 4 | 0.8617 | known |
| D00376, Meprobamate | hsa:2565, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma1 | 0.8613 | known |
| D00407, Methylprednisolone | hsa:2908, (RefSeq) nuclear receptor subfamily 3 group C member 1 | 0.861 | known |
| D00138, Scopolamine | hsa:1128, (RefSeq) cholinergic receptor muscarinic 1 | 0.86 | known |
| D00378, Timolol | hsa:153, (RefSeq) adrenoceptor beta 1 | 0.8596 | known |
| D00138, Scopolamine | hsa:1129, (RefSeq) cholinergic receptor muscarinic 2 | 0.8595 | known |
| D00403, Methotrimeprazine | hsa:3356, (RefSeq) 5-hydroxytryptamine receptor 2A | 0.8595 | known |
| D00147, Hyoscyamine | hsa:1132, (RefSeq) cholinergic receptor muscarinic 4 | 0.8584 | known |
| D00131, Disulfiram | hsa:219, (RefSeq) aldehyde dehydrogenase 1 family member B1 | 0.8575 | known |
| D00131, Disulfiram | hsa:217, (RefSeq) aldehyde dehydrogenase 2 family member | 0.8571 | known |
| D00472, Prednisolone | hsa:2908, (RefSeq) nuclear receptor subfamily 3 group C member 1 | 0.8567 | known |
| D00376, Meprobamate | hsa:2560, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta1 | 0.8564 | known |
| D00383, Trandolapril | hsa:1636, (RefSeq) angiotensin I converting enzyme | 0.8564 | known |
| D00088, Hydrocortisone | hsa:2908, (RefSeq) nuclear receptor subfamily 3 group C member 1 | 0.8562 | known |
| D00376, Meprobamate | hsa:2561, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta2 | 0.856 | known |
| D00147, Hyoscyamine | hsa:1131, (RefSeq) cholinergic receptor muscarinic 3 | 0.856 | known |
| D00458, Quetiapine fumarate | hsa:148, (RefSeq) adrenoceptor alpha 1A | 0.8559 | known |
| D00216, Acarbose | hsa:280, (RefSeq) amylase alpha 2B | 0.8557 | known |
| D00216, Acarbose | hsa:279, (RefSeq) amylase alpha 2A | 0.8556 | known |
| D00267, Chlordiazepoxide | hsa:2568, (RefSeq) gamma-aminobutyric acid type A receptor subunit pi | 0.855 | known |
| D00270, Chlorpromazine | hsa:3358, (RefSeq) 5-hydroxytryptamine receptor 2C | 0.8541 | known |
| D00147, Hyoscyamine | hsa:1129, (RefSeq) cholinergic receptor muscarinic 2 | 0.8528 | known |
| D00147, Hyoscyamine | hsa:1128, (RefSeq) cholinergic receptor muscarinic 1 | 0.8527 | known |
| D00399, Valproic acid | hsa:253175, (RefSeq) chromodomain Y-linked 1B | 0.8522 | known |
| D00399, Valproic acid | hsa:203611, (RefSeq) chromodomain Y-linked 2B | 0.8519 | known |
| D00479, Prochlorperazine maleate | hsa:1813, (RefSeq) dopamine receptor D2 | 0.8501 | known |
| D00376, Meprobamate | hsa:2562, (RefSeq) gamma-aminobutyric acid type A receptor subunit beta3 | 0.8499 | known |
| D00113, Atropine | hsa:1132, (RefSeq) cholinergic receptor muscarinic 4 | 0.8498 | known |
| D00376, Meprobamate | hsa:2557, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha4 | 0.8487 | known |
| D00113, Atropine | hsa:1131, (RefSeq) cholinergic receptor muscarinic 3 | 0.8484 | known |
| D00458, Quetiapine fumarate | hsa:146, (RefSeq) adrenoceptor alpha 1D | 0.8481 | known |
| D00376, Meprobamate | hsa:2567, (RefSeq) gamma-aminobutyric acid type A receptor subunit gamma3 | 0.8479 | known |
| D00359, Lovastatin | hsa:3156, (RefSeq) 3-hydroxy-3-methylglutaryl-CoA reductase | 0.8463 | known |
| D00426, Risperidone | hsa:147, (RefSeq) adrenoceptor alpha 1B | 0.8462 | known |
| D00113, Atropine | hsa:1128, (RefSeq) cholinergic receptor muscarinic 1 | 0.8457 | known |
| D00325, Fluocinonide | hsa:2908, (RefSeq) nuclear receptor subfamily 3 group C member 1 | 0.8455 | known |
| D00113, Atropine | hsa:1129, (RefSeq) cholinergic receptor muscarinic 2 | 0.8446 | known |
| D00216, Acarbose | hsa:2595, (RefSeq) glucosidase alpha | 0.842 | known |
| D00283, Clozapine | hsa:147, (RefSeq) adrenoceptor alpha 1B | 0.8419 | known |
| D00216, Acarbose | hsa:2548, (RefSeq) alpha glucosidase | 0.8419 | known |
| D00454, Olanzapine | hsa:147, (RefSeq) adrenoceptor alpha 1B | 0.8411 | known |
| D00255, Carvedilol | hsa:153, (RefSeq) adrenoceptor beta 1 | 0.8384 | known |
| D00165, Hydrocortisone acetate | hsa:2908, (RefSeq) nuclear receptor subfamily 3 group C member 1 | 0.8378 | known |
| D00481, Propantheline bromide | hsa:1132, (RefSeq) cholinergic receptor muscarinic 4 | 0.8376 | known |
| D00473, Prednisone | hsa:2908, (RefSeq) nuclear receptor subfamily 3 group C member 1 | 0.8365 | known |
| D00376, Meprobamate | hsa:2563, (RefSeq) gamma-aminobutyric acid type A receptor subunit delta | 0.8358 | known |
| D00376, Meprobamate | hsa:2564, (RefSeq) gamma-aminobutyric acid type A receptor subunit epsilon | 0.8356 | known |
| D00244, Betamethasone | hsa:2908, (RefSeq) nuclear receptor subfamily 3 group C member 1 | 0.8352 | known |
| D00421, Ramipril | hsa:1636, (RefSeq) angiotensin I converting enzyme | 0.8347 | known |
| D00481, Propantheline bromide | hsa:1131, (RefSeq) cholinergic receptor muscarinic 3 | 0.8343 | known |
| D00251, Captopril | hsa:1636, (RefSeq) angiotensin I converting enzyme | 0.8341 | known |
| D00270, Chlorpromazine | hsa:1132, (RefSeq) cholinergic receptor muscarinic 4 | 0.8337 | known |
| D00131, Disulfiram | hsa:224, (RefSeq) aldehyde dehydrogenase 3 family member A2 | 0.833 | known |
| D00138, Scopolamine | hsa:1133, (RefSeq) cholinergic receptor muscarinic 5 | 0.833 | known |
| D00454, Olanzapine | hsa:148, (RefSeq) adrenoceptor alpha 1A | 0.832 | known |
| D00227, Aminophylline | hsa:135, (RefSeq) adenosine A2a receptor | 0.8316 | known |
| D00371, Theophylline | hsa:135, (RefSeq) adenosine A2a receptor | 0.8316 | known |
| D00481, Propantheline bromide | hsa:1128, (RefSeq) cholinergic receptor muscarinic 1 | 0.8312 | known |
| D00481, Propantheline bromide | hsa:1129, (RefSeq) cholinergic receptor muscarinic 2 | 0.8308 | known |
| D00095, Epinephrine | hsa:155, (RefSeq) adrenoceptor beta 3 | 0.8307 | known |
| D00246, Budesonide | hsa:2908, (RefSeq) nuclear receptor subfamily 3 group C member 1 | 0.8306 | known |
| D00483, Propranolol hydrochloride | hsa:153, (RefSeq) adrenoceptor beta 1 | 0.8304 | known |
| D00362, Lisinopril | hsa:1636, (RefSeq) angiotensin I converting enzyme | 0.8295 | known |
| D00147, Hyoscyamine | hsa:1133, (RefSeq) cholinergic receptor muscarinic 5 | 0.8291 | known |
| D00376, Meprobamate | hsa:2568, (RefSeq) gamma-aminobutyric acid type A receptor subunit pi | 0.8291 | known |
| D00397, Tropicamide | hsa:1132, (RefSeq) cholinergic receptor muscarinic 4 | 0.8285 | known |
| D00283, Clozapine | hsa:148, (RefSeq) adrenoceptor alpha 1A | 0.8285 | known |
| D00385, Triamcinolone | hsa:2908, (RefSeq) nuclear receptor subfamily 3 group C member 1 | 0.8278 | known |
| D00403, Methotrimeprazine | hsa:1813, (RefSeq) dopamine receptor D2 | 0.8275 | known |
| D00095, Epinephrine | hsa:147, (RefSeq) adrenoceptor alpha 1B | 0.8266 | known |
| D00304, Divalproex sodium | hsa:18, (RefSeq) 4-aminobutyrate aminotransferase | 0.8261 | known |
| D00397, Tropicamide | hsa:1131, (RefSeq) cholinergic receptor muscarinic 3 | 0.826 | known |
| D00454, Olanzapine | hsa:146, (RefSeq) adrenoceptor alpha 1D | 0.8252 | known |
| D00434, Simvastatin | hsa:3156, (RefSeq) 3-hydroxy-3-methylglutaryl-CoA reductase | 0.8245 | known |
| D00426, Risperidone | hsa:146, (RefSeq) adrenoceptor alpha 1D | 0.8244 | known |
| D00397, Tropicamide | hsa:1128, (RefSeq) cholinergic receptor muscarinic 1 | 0.8232 | known |
| D00283, Clozapine | hsa:146, (RefSeq) adrenoceptor alpha 1D | 0.8228 | known |
| D00283, Clozapine | hsa:1813, (RefSeq) dopamine receptor D2 | 0.8225 | known |
| D00397, Tropicamide | hsa:1129, (RefSeq) cholinergic receptor muscarinic 2 | 0.8224 | known |
| D00113, Atropine | hsa:1133, (RefSeq) cholinergic receptor muscarinic 5 | 0.8219 | known |
| D00491, Paclitaxel | hsa:10383, (RefSeq) tubulin beta 4B class IVb | 0.8218 | known |
| D00076, Noradrenaline | hsa:155, (RefSeq) adrenoceptor beta 3 | 0.82 | known |
| D00456, Ondansetron | hsa:285242, (RefSeq) 5-hydroxytryptamine receptor 3E | 0.8198 | known |
| D00491, Paclitaxel | hsa:10382, (RefSeq) tubulin beta 4A class IVa | 0.8197 | known |
| D00491, Paclitaxel | hsa:203068, (RefSeq) tubulin beta class I | 0.819 | known |
| D00324, Flunisolide | hsa:2908, (RefSeq) nuclear receptor subfamily 3 group C member 1 | 0.8187 | known |
| D00227, Aminophylline | hsa:134, (RefSeq) adenosine A1 receptor | 0.8185 | known |
| D00371, Theophylline | hsa:134, (RefSeq) adenosine A1 receptor | 0.8177 | known |
| D00374, Thiothixene | hsa:1813, (RefSeq) dopamine receptor D2 | 0.8176 | known |
| D00426, Risperidone | hsa:148, (RefSeq) adrenoceptor alpha 1A | 0.8173 | known |
| D00155, Pentostatin | hsa:100, (RefSeq) adenosine deaminase | 0.8151 | known |
| D00136, Haloperidol | hsa:1813, (RefSeq) dopamine receptor D2 | 0.8135 | known |
| D00076, Noradrenaline | hsa:147, (RefSeq) adrenoceptor alpha 1B | 0.8134 | known |
| D00414, Zileuton | hsa:240, (RefSeq) arachidonate 5-lipoxygenase | 0.8129 | known |
| D00219, Acetohexamide | hsa:10060, (RefSeq) ATP binding cassette subfamily C member 9 | 0.8126 | known |
| D00124, Ephedrine | hsa:155, (RefSeq) adrenoceptor beta 3 | 0.8123 | known |
| D00095, Epinephrine | hsa:151, (RefSeq) adrenoceptor alpha 2B | 0.8122 | known |
| D00485, Pseudoephedrine hydrochloride | hsa:155, (RefSeq) adrenoceptor beta 3 | 0.8122 | known |
| D00095, Epinephrine | hsa:146, (RefSeq) adrenoceptor alpha 1D | 0.8117 | known |
| D00399, Valproic acid | hsa:18, (RefSeq) 4-aminobutyrate aminotransferase | 0.8113 | known |
| D00095, Epinephrine | hsa:150, (RefSeq) adrenoceptor alpha 2A | 0.81 | known |
| D00405, Methyldopa | hsa:150, (RefSeq) adrenoceptor alpha 2A | 0.8098 | known |
| D00481, Propantheline bromide | hsa:1133, (RefSeq) cholinergic receptor muscarinic 5 | 0.8096 | known |
| D00270, Chlorpromazine | hsa:1129, (RefSeq) cholinergic receptor muscarinic 2 | 0.8095 | known |
| D00095, Epinephrine | hsa:154, (RefSeq) adrenoceptor beta 2 | 0.8094 | known |
| D00076, Noradrenaline | hsa:151, (RefSeq) adrenoceptor alpha 2B | 0.8083 | known |
| D00405, Methyldopa | hsa:151, (RefSeq) adrenoceptor alpha 2B | 0.8077 | known |
| D00328, Flurandrenolide | hsa:2908, (RefSeq) nuclear receptor subfamily 3 group C member 1 | 0.8068 | known |
| D00095, Epinephrine | hsa:148, (RefSeq) adrenoceptor alpha 1A | 0.8066 | known |
| D00076, Noradrenaline | hsa:150, (RefSeq) adrenoceptor alpha 2A | 0.8062 | known |
| D00485, Pseudoephedrine hydrochloride | hsa:147, (RefSeq) adrenoceptor alpha 1B | 0.8059 | known |
| D00456, Ondansetron | hsa:170572, (RefSeq) 5-hydroxytryptamine receptor 3C | 0.8055 | known |
| D00493, Prochlorperazine | hsa:1813, (RefSeq) dopamine receptor D2 | 0.8054 | known |
| D00335, Glipizide | hsa:10060, (RefSeq) ATP binding cassette subfamily C member 9 | 0.8045 | known |
| D00458, Quetiapine fumarate | hsa:1814, (RefSeq) dopamine receptor D3 | 0.8041 | known |
| D00270, Chlorpromazine | hsa:1128, (RefSeq) cholinergic receptor muscarinic 1 | 0.8039 | known |
| D00456, Ondansetron | hsa:200909, (RefSeq) 5-hydroxytryptamine receptor 3D | 0.8037 | known |
| D00124, Ephedrine | hsa:147, (RefSeq) adrenoceptor alpha 1B | 0.8031 | known |
| D00459, Quinapril hydrochloride | hsa:1636, (RefSeq) angiotensin I converting enzyme | 0.8022 | known |
| D00181, Argatroban | hsa:2147, (RefSeq) coagulation factor II | 0.8021 | known |
| D00397, Tropicamide | hsa:1133, (RefSeq) cholinergic receptor muscarinic 5 | 0.8011 | known |
| D00410, Metyrapone | hsa:1584, (RefSeq) cytochrome P450 family 11 subfamily B member 1 | 0.8008 | known |
| D00095, Epinephrine | hsa:153, (RefSeq) adrenoceptor beta 1 | 0.8 | known |
| D00491, Paclitaxel | hsa:10381, (RefSeq) tubulin beta 3 class III | 0.8 | known |
| D00485, Pseudoephedrine hydrochloride | hsa:151, (RefSeq) adrenoceptor alpha 2B | 0.7991 | known |
| D00076, Noradrenaline | hsa:154, (RefSeq) adrenoceptor beta 2 | 0.7989 | known |
| D00076, Noradrenaline | hsa:146, (RefSeq) adrenoceptor alpha 1D | 0.7987 | known |
| D00485, Pseudoephedrine hydrochloride | hsa:150, (RefSeq) adrenoceptor alpha 2A | 0.7968 | known |
| D00331, Furosemide | hsa:2554, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha1 | 0.7962 | known |
| D00270, Chlorpromazine | hsa:1131, (RefSeq) cholinergic receptor muscarinic 3 | 0.7955 | known |
| D00271, Chlorpropamide | hsa:10060, (RefSeq) ATP binding cassette subfamily C member 9 | 0.7952 | known |
| D00331, Furosemide | hsa:2555, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha2 | 0.7951 | known |
| D00306, Dronabinol | hsa:1268, (RefSeq) cannabinoid receptor 1 | 0.794 | known |
| D00076, Noradrenaline | hsa:148, (RefSeq) adrenoceptor alpha 1A | 0.7933 | known |
| D00124, Ephedrine | hsa:151, (RefSeq) adrenoceptor alpha 2B | 0.793 | known |
| D00403, Methotrimeprazine | hsa:151, (RefSeq) adrenoceptor alpha 2B | 0.7929 | known |
| D00485, Pseudoephedrine hydrochloride | hsa:154, (RefSeq) adrenoceptor beta 2 | 0.7917 | known |
| D00485, Pseudoephedrine hydrochloride | hsa:146, (RefSeq) adrenoceptor alpha 1D | 0.7914 | known |
| D00124, Ephedrine | hsa:154, (RefSeq) adrenoceptor beta 2 | 0.7913 | known |
| D00373, Thioridazine | hsa:1813, (RefSeq) dopamine receptor D2 | 0.7911 | known |
| D00124, Ephedrine | hsa:150, (RefSeq) adrenoceptor alpha 2A | 0.7908 | known |
| D00331, Furosemide | hsa:2558, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha5 | 0.7904 | known |
| D00292, Dexamethasone | hsa:2908, (RefSeq) nuclear receptor subfamily 3 group C member 1 | 0.7903 | known |
| D00270, Chlorpromazine | hsa:1133, (RefSeq) cholinergic receptor muscarinic 5 | 0.7893 | known |
| D00076, Noradrenaline | hsa:153, (RefSeq) adrenoceptor beta 1 | 0.7893 | known |
| D00454, Olanzapine | hsa:3269, (RefSeq) histamine receptor H1 | 0.7887 | known |
| D00124, Ephedrine | hsa:146, (RefSeq) adrenoceptor alpha 1D | 0.7885 | known |
| D00270, Chlorpromazine | hsa:151, (RefSeq) adrenoceptor alpha 2B | 0.7884 | known |
| D00331, Furosemide | hsa:2556, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha3 | 0.788 | known |
| D00403, Methotrimeprazine | hsa:150, (RefSeq) adrenoceptor alpha 2A | 0.7874 | known |
| D00293, Diazepam | hsa:2741, (RefSeq) glycine receptor alpha 1 | 0.7871 | training - new |
| D00458, Quetiapine fumarate | hsa:3269, (RefSeq) histamine receptor H1 | 0.7867 | known |
| D00270, Chlorpromazine | hsa:3269, (RefSeq) histamine receptor H1 | 0.7866 | known |
| D00485, Pseudoephedrine hydrochloride | hsa:148, (RefSeq) adrenoceptor alpha 1A | 0.7864 | known |
| D00312, Estrone sodium sulfate | hsa:2099, (RefSeq) estrogen receptor 1 | 0.7862 | known |
| D00095, Epinephrine | hsa:152, (RefSeq) adrenoceptor alpha 2C | 0.7861 | known |
| D00312, Estrone sodium sulfate | hsa:2100, (RefSeq) estrogen receptor 2 | 0.7857 | known |
| D00059, Levodopa | hsa:1813, (RefSeq) dopamine receptor D2 | 0.7855 | known |
| D00270, Chlorpromazine | hsa:150, (RefSeq) adrenoceptor alpha 2A | 0.7851 | known |
| D00379, Tolazamide | hsa:10060, (RefSeq) ATP binding cassette subfamily C member 9 | 0.7846 | known |
| D00142, Methotrexate | hsa:1719, (RefSeq) dihydrofolate reductase | 0.7831 | known |
| D00124, Ephedrine | hsa:148, (RefSeq) adrenoceptor alpha 1A | 0.783 | known |
| D00076, Noradrenaline | hsa:152, (RefSeq) adrenoceptor alpha 2C | 0.7823 | known |
| D00405, Methyldopa | hsa:152, (RefSeq) adrenoceptor alpha 2C | 0.7809 | known |
| D00124, Ephedrine | hsa:153, (RefSeq) adrenoceptor beta 1 | 0.7807 | known |
| D00485, Pseudoephedrine hydrochloride | hsa:153, (RefSeq) adrenoceptor beta 1 | 0.7799 | known |
| D00403, Methotrimeprazine | hsa:147, (RefSeq) adrenoceptor alpha 1B | 0.7791 | known |
| D00283, Clozapine | hsa:3356, (RefSeq) 5-hydroxytryptamine receptor 2A | 0.7789 | known |
| D00255, Carvedilol | hsa:155, (RefSeq) adrenoceptor beta 3 | 0.7779 | known |
| D00420, Mitotane | hsa:1586, (RefSeq) cytochrome P450 family 17 subfamily A member 1 | 0.7777 | known |
| D00059, Levodopa | hsa:1812, (RefSeq) dopamine receptor D1 | 0.7757 | known |
| D00403, Methotrimeprazine | hsa:3358, (RefSeq) 5-hydroxytryptamine receptor 2C | 0.7752 | known |
| D00281, Clonidine | hsa:150, (RefSeq) adrenoceptor alpha 2A | 0.7741 | known |
| D00152, Phloroglucinol | hsa:1312, (RefSeq) catechol-O-methyltransferase | 0.7736 | known |
| D00281, Clonidine | hsa:151, (RefSeq) adrenoceptor alpha 2B | 0.7733 | known |
| D00485, Pseudoephedrine hydrochloride | hsa:152, (RefSeq) adrenoceptor alpha 2C | 0.7733 | known |
| D00494, Promethazine | hsa:3269, (RefSeq) histamine receptor H1 | 0.771 | known |
| D00059, Levodopa | hsa:1814, (RefSeq) dopamine receptor D3 | 0.7696 | known |
| D00465, Oxybutynin | hsa:1128, (RefSeq) cholinergic receptor muscarinic 1 | 0.7693 | known |
| D00308, Droperidol | hsa:1813, (RefSeq) dopamine receptor D2 | 0.7674 | known |
| D00124, Ephedrine | hsa:152, (RefSeq) adrenoceptor alpha 2C | 0.7673 | known |
| D00403, Methotrimeprazine | hsa:152, (RefSeq) adrenoceptor alpha 2C | 0.7669 | known |
| D00270, Chlorpromazine | hsa:3357, (RefSeq) 5-hydroxytryptamine receptor 2B | 0.7665 | known |
| D00331, Furosemide | hsa:2559, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha6 | 0.7654 | known |
| D00365, Lorazepam | hsa:2741, (RefSeq) glycine receptor alpha 1 | 0.7652 | training - new |
| D00241, Baclofen | hsa:2550, (RefSeq) gamma-aminobutyric acid type B receptor subunit 1 | 0.7646 | known |
| D00370, Temazepam | hsa:2741, (RefSeq) glycine receptor alpha 1 | 0.7643 | training - new |
| D00415, Zolmitriptan | hsa:3352, (RefSeq) 5-hydroxytryptamine receptor 1D | 0.7641 | known |
| D00415, Zolmitriptan | hsa:3351, (RefSeq) 5-hydroxytryptamine receptor 1B | 0.7632 | known |
| D00465, Oxybutynin | hsa:1131, (RefSeq) cholinergic receptor muscarinic 3 | 0.763 | known |
| D00432, Nadolol | hsa:155, (RefSeq) adrenoceptor beta 3 | 0.7625 | known |
| D00270, Chlorpromazine | hsa:152, (RefSeq) adrenoceptor alpha 2C | 0.7623 | known |
| D00387, Triazolam | hsa:2741, (RefSeq) glycine receptor alpha 1 | 0.7618 | training - new |
| D00331, Furosemide | hsa:2557, (RefSeq) gamma-aminobutyric acid type A receptor subunit alpha4 | 0.7614 | known |
| D00378, Timolol | hsa:155, (RefSeq) adrenoceptor beta 3 | 0.761 | known |
| D00306, Dronabinol | hsa:1269, (RefSeq) cannabinoid receptor 2 | 0.7607 | known |
| D00255, Carvedilol | hsa:147, (RefSeq) adrenoceptor alpha 1B | 0.7601 | known |
| D00480, Promethazine hydrochloride | hsa:3269, (RefSeq) histamine receptor H1 | 0.7596 | known |
| D00451, Sumatriptan | hsa:3352, (RefSeq) 5-hydroxytryptamine receptor 1D | 0.7595 | known |
| D00270, Chlorpromazine | hsa:3356, (RefSeq) 5-hydroxytryptamine receptor 2A | 0.7591 | known |
| D00403, Methotrimeprazine | hsa:146, (RefSeq) adrenoceptor alpha 1D | 0.7589 | known |
| D00451, Sumatriptan | hsa:3351, (RefSeq) 5-hydroxytryptamine receptor 1B | 0.7586 | known |
| D00225, Alprazolam | hsa:2741, (RefSeq) glycine receptor alpha 1 | 0.7576 | training - new |
| D00283, Clozapine | hsa:1815, (RefSeq) dopamine receptor D4 | 0.7573 | known |
| D00465, Oxybutynin | hsa:1129, (RefSeq) cholinergic receptor muscarinic 2 | 0.7558 | known |
| D00454, Olanzapine | hsa:1814, (RefSeq) dopamine receptor D3 | 0.7557 | known |
| D00440, Nizatidine | hsa:3274, (RefSeq) histamine receptor H2 | 0.7553 | known |
| D00234, Astemizole | hsa:3269, (RefSeq) histamine receptor H1 | 0.7544 | known |
| D00255, Carvedilol | hsa:154, (RefSeq) adrenoceptor beta 2 | 0.7537 | known |
| D00432, Nadolol | hsa:154, (RefSeq) adrenoceptor beta 2 | 0.7517 | known |
| D00156, Glycyrrhetinic acid | hsa:3290, (RefSeq) hydroxysteroid 11-beta dehydrogenase 1 | 0.751 | known |
| D00378, Timolol | hsa:154, (RefSeq) adrenoceptor beta 2 | 0.7503 | known |
| D00255, Carvedilol | hsa:146, (RefSeq) adrenoceptor alpha 1D | 0.7483 | known |
| D00403, Methotrimeprazine | hsa:148, (RefSeq) adrenoceptor alpha 1A | 0.7477 | known |
| D00329, Flurazepam | hsa:2741, (RefSeq) glycine receptor alpha 1 | 0.7464 | training - new |
| D00281, Clonidine | hsa:152, (RefSeq) adrenoceptor alpha 2C | 0.7462 | known |
| D00457, Quazepam | hsa:2741, (RefSeq) glycine receptor alpha 1 | 0.7438 | training - new |
| D00295, Cimetidine | hsa:3274, (RefSeq) histamine receptor H2 | 0.743 | known |
| D00311, Estazolam | hsa:2741, (RefSeq) glycine receptor alpha 1 | 0.7426 | training - new |
| D00364, Loratadine | hsa:3269, (RefSeq) histamine receptor H1 | 0.7419 | known |
| D00318, Famotidine | hsa:3274, (RefSeq) histamine receptor H2 | 0.7415 | known |
| D00492, Pancuronium bromide | hsa:1146, (RefSeq) cholinergic receptor nicotinic gamma subunit | 0.7415 | known |
| D00105, Estradiol | hsa:2099, (RefSeq) estrogen receptor 1 | 0.7395 | known |
| D00105, Estradiol | hsa:2100, (RefSeq) estrogen receptor 2 | 0.7389 | known |
| D00255, Carvedilol | hsa:148, (RefSeq) adrenoceptor alpha 1A | 0.7386 | known |
| D00280, Clonazepam | hsa:2741, (RefSeq) glycine receptor alpha 1 | 0.738 | training - new |
| D00059, Levodopa | hsa:1815, (RefSeq) dopamine receptor D4 | 0.7358 | known |
| D00492, Pancuronium bromide | hsa:1145, (RefSeq) cholinergic receptor nicotinic epsilon subunit | 0.7353 | known |
| D00422, Ranitidine | hsa:3274, (RefSeq) histamine receptor H2 | 0.7349 | known |
| D00470, Prazepam | hsa:2741, (RefSeq) glycine receptor alpha 1 | 0.7334 | training - new |
| D00483, Propranolol hydrochloride | hsa:155, (RefSeq) adrenoceptor beta 3 | 0.733 | known |
| D00357, Losartan potassium | hsa:185, (RefSeq) angiotensin II receptor type 1 | 0.732 | known |
| D00458, Quetiapine fumarate | hsa:1815, (RefSeq) dopamine receptor D4 | 0.7319 | known |
| D00430, Secobarbital | hsa:2741, (RefSeq) glycine receptor alpha 1 | 0.7314 | training - new |
| D00492, Pancuronium bromide | hsa:1144, (RefSeq) cholinergic receptor nicotinic delta subunit | 0.7264 | known |
| D00293, Diazepam | hsa:2742, (RefSeq) glycine receptor alpha 2 | 0.7253 | training - new |
| D00483, Propranolol hydrochloride | hsa:154, (RefSeq) adrenoceptor beta 2 | 0.7221 | known |
| D00400, Valsartan | hsa:185, (RefSeq) angiotensin II receptor type 1 | 0.721 | known |
| D00499, Pentobarbital | hsa:2741, (RefSeq) glycine receptor alpha 1 | 0.7185 | training - new |
| D00458, Quetiapine fumarate | hsa:3356, (RefSeq) 5-hydroxytryptamine receptor 2A | 0.7169 | known |
| D00492, Pancuronium bromide | hsa:1140, (RefSeq) cholinergic receptor nicotinic beta 1 subunit | 0.7124 | known |
| D00365, Lorazepam | hsa:2742, (RefSeq) glycine receptor alpha 2 | 0.7053 | training - new |
| D00370, Temazepam | hsa:2742, (RefSeq) glycine receptor alpha 2 | 0.7043 | training - new |
| D00387, Triazolam | hsa:2742, (RefSeq) glycine receptor alpha 2 | 0.7022 | training - new |
| D00267, Chlordiazepoxide | hsa:2741, (RefSeq) glycine receptor alpha 1 | 0.7005 | training - new |
| D00403, Methotrimeprazine | hsa:3357, (RefSeq) 5-hydroxytryptamine receptor 2B | 0.6981 | known |
| D00225, Alprazolam | hsa:2742, (RefSeq) glycine receptor alpha 2 | 0.6981 | training - new |
| D00283, Clozapine | hsa:3350, (RefSeq) 5-hydroxytryptamine receptor 1A | 0.6968 | known |
| D00329, Flurazepam | hsa:2742, (RefSeq) glycine receptor alpha 2 | 0.688 | training - new |
| D00457, Quazepam | hsa:2742, (RefSeq) glycine receptor alpha 2 | 0.6856 | training - new |
| D00311, Estazolam | hsa:2742, (RefSeq) glycine receptor alpha 2 | 0.6845 | training - new |
| D00280, Clonazepam | hsa:2742, (RefSeq) glycine receptor alpha 2 | 0.6804 | training - new |
| D00376, Meprobamate | hsa:2741, (RefSeq) glycine receptor alpha 1 | 0.6803 | training - new |
| D00470, Prazepam | hsa:2742, (RefSeq) glycine receptor alpha 2 | 0.6759 | training - new |
| D00430, Secobarbital | hsa:2742, (RefSeq) glycine receptor alpha 2 | 0.6739 | training - new |
| D00300, Diphenhydramine | hsa:3269, (RefSeq) histamine receptor H1 | 0.6694 | known |
| D00499, Pentobarbital | hsa:2742, (RefSeq) glycine receptor alpha 2 | 0.6624 | training - new |
| D00492, Pancuronium bromide | hsa:1134, (RefSeq) cholinergic receptor nicotinic alpha 1 subunit | 0.6622 | known |
| D00267, Chlordiazepoxide | hsa:2742, (RefSeq) glycine receptor alpha 2 | 0.6457 | training - new |
| D00454, Olanzapine | hsa:3358, (RefSeq) 5-hydroxytryptamine receptor 2C | 0.644 | known |
| D00376, Meprobamate | hsa:2742, (RefSeq) glycine receptor alpha 2 | 0.6271 | training - new |
| D00405, Methyldopa | hsa:1644, (RefSeq) dopa decarboxylase | 0.6154 | known |
| D00374, Thiothixene | hsa:1812, (RefSeq) dopamine receptor D1 | 0.6148 | known |
| D00059, Levodopa | hsa:1816, (RefSeq) dopamine receptor D5 | 0.6125 | known |
| D00293, Diazepam | hsa:2743, (RefSeq) glycine receptor beta | 0.5939 | training - new |
| D00426, Risperidone | hsa:3356, (RefSeq) 5-hydroxytryptamine receptor 2A | 0.5927 | known |
| D00365, Lorazepam | hsa:2743, (RefSeq) glycine receptor beta | 0.5778 | training - new |
| D00370, Temazepam | hsa:2743, (RefSeq) glycine receptor beta | 0.577 | training - new |
| D00387, Triazolam | hsa:2743, (RefSeq) glycine receptor beta | 0.5752 | training - new |
| D00225, Alprazolam | hsa:2743, (RefSeq) glycine receptor beta | 0.5716 | training - new |
| D00329, Flurazepam | hsa:2743, (RefSeq) glycine receptor beta | 0.5636 | training - new |
| D00457, Quazepam | hsa:2743, (RefSeq) glycine receptor beta | 0.5616 | training - new |
| D00311, Estazolam | hsa:2743, (RefSeq) glycine receptor beta | 0.5605 | training - new |
| D00280, Clonazepam | hsa:2743, (RefSeq) glycine receptor beta | 0.5571 | training - new |
| D00470, Prazepam | hsa:2743, (RefSeq) glycine receptor beta | 0.5538 | training - new |
| D00430, Secobarbital | hsa:2743, (RefSeq) glycine receptor beta | 0.5522 | training - new |
| D00499, Pentobarbital | hsa:2743, (RefSeq) glycine receptor beta | 0.5424 | training - new |
| D00267, Chlordiazepoxide | hsa:2743, (RefSeq) glycine receptor beta | 0.5285 | training - new |
| D00376, Meprobamate | hsa:2743, (RefSeq) glycine receptor beta | 0.5132 | training - new |